Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Preliminary Antitumor Activity and Safety of EGFR-TKIs Combined With PD-1 Monoclonal Antibody as First-Line Therapy in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

NCT07637448 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT07637448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07637448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Preliminary Antitumor Activity and Safety of EGFR-TKIs Combined With PD-1 Monoclonal Antibody as First-Line Therapy in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
May 21, 2026
Completion date
March 1, 2030
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, lung cancer non-small cell cancer (nsclc), pd-1 antibody